Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284387 · ClinicalTrials.gov registry record · Phase 2
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT01284387: Completed Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT01284387 is a Phase 2 study that has completed, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 126 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01284387, a Phase 2 study, has completed, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
A Phase II clinical research study to evaluate the efficacy and safety of two different dose levels of an injectable investigational treatment (ACC-001) in subjects with Mild-to-Moderate Alzheimer's disease. ACC-001 (vanutide cridificar) is a beta amyloid fragment attached to a carrier protein. It is intended to help induce an antibody response against beta amyloid and is administered as an intramuscular injection.
Interventions
- BIOLOGICAL ACC-001 (vanutide cridificar)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01284387
The ClinicalTrials.gov registry entry for NCT01284387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACC-001 (vanutide cridificar) is the first listed.
NCT01284387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01284387 about?
NCT01284387 is a clinical study titled "Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease". A Phase II clinical research study to evaluate the efficacy and safety of two different dose levels of an injectable investigational treatment (ACC-001) in subjects with Mild-to-Moderate Alzheimer's disease. ACC-001 (vanutide cridificar) is a beta amyloid fragment attached to a carrier protein. It i...
What is the current status of trial NCT01284387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2011-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01284387?
The interventions under investigation include: ACC-001 (vanutide cridificar) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01284387?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.